Novavax (NASDAQ: NVAX) is a biotechnology company that develops and commercializes protein-based vaccines, with its primary product being a COVID-19 vaccine built on its recombinant nanoparticle technology platform. Revenue is generated through product sales, supply agreements, and licensing or partnership arrangements with governments and international health organizations. The 10-K filed 2026-02-26 (accession 000100069426000007) does not provide sufficient detail in the excerpts supplied to confirm specific revenue figures, segment breakdowns, geographic mix percentages, named competitors, or leadership tenure. Based solely on the available filing excerpts, further specifics on market position, customer concentration, capital structure, and founding history cannot be confirmed and are therefore omitted. The company is incorporated in the United States and files with the SEC as a well-known seasoned issuer as of the filing date.

Revenue model

Product sales, government and multilateral supply agreements, and partnership or licensing arrangements for its COVID-19 vaccine and vaccine technology platform.

Products and services

Protein-based recombinant nanoparticle COVID-19 vaccine; proprietary vaccine technology platform.

Customers and end markets

Governments and international health organizations purchasing COVID-19 vaccines; public health end market.

Value-chain role

Vaccine developer and manufacturer; direct supplier to government procurement bodies and health authorities.

Source: SEC 10-K, filed 2026-02-26

Industry: Biological Products, (No Diagnostic Substances) Peers: Agios Pharmaceuticals Inc BridgeBio Pharma Inc Day One Biopharmaceuticals, Inc. Travere Therapeutics Inc Iovance Biotherapeutics Inc Ironwood Pharmaceuticals Inc Myriad Genetics Inc Vaxcyte Inc Xencor Inc